Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response.

• DOI: 10.1164/ajrccm.155.6.9196083
• Publication Date: 2013-04-04T21:54:39Z
• Authors: L P Boulet; K R Chapman; J Côté; S Kalra; R Bhagat; V A Swystun; M Laviolette; L D Cleland; F Deschesnes; J Q Su; A DeVault; R B Fick; D W Cockcroft
• Keywords: Methacholine

Inhaled allergens, acting through IgE-dependent mechanisms, are important triggers of asthma symptoms and inducers airway hyperresponsiveness inflammation. The effect anti-IgE recombinant humanized monoclonal antibody-E25 (rhuMAb-E25) on the provocation concentration allergen causing a 15% fall in FEV1 (allergen PC15) during allergen-induced early asthmatic response (EAR) was assessed multicenter, randomized, double-blind, parallel group study. Ten 11 allergic subjects randomized to receive intravenous rhuMAb-E25, 2 mg/kg study day 0 1 Days 7, 14, 28, 42, 56, 70 completed study; nine received placebo. PC15 measured -1, 27, 55, 77 methacholine PC20 -2, 76. rhuMAb-25 well tolerated only one patient (active group) withdrawn because generalized urticarial rash after first dose. Compared with baseline values (Day -1), median were increased by 2.3, 2.2, 2.7 doubling doses (delta log PC15/0.3) respectively rhuMAb-E25 -0.3, +0.1, -0.8 placebo (p < or = 0.002). Methacholine improved slightly this change becoming statistically significant Day 76 0.05); no observed group. Mean serum-free IgE fell 89% while there inhibitory effects EAR suggest that it may be an effective, novel antiallergic treatment for asthma.